Japanese MHW 1995 Budget Increases 3.4%

23 January 1995

The Japanese government has approved a budget for the Ministry of Health and Welfare of 13,974.6 billion yen ($141.04 billion) for fiscal 1995, a rise of 3.4% on fiscal 1994. It agreed to nearly all the MHW's requests, notes Pharma Japan, with one proposal initially turned down by the Ministry of Finance, for 302 million yen ($3.04 million) to be used for the third-party evaluation of hospital functions, finally being approved after talks at director-general level.

Within this total, the annual budget for the Pharmaceutical Affairs Bureau has been raised 6% to 7.99 billion yen ($80.65 million). This includes a doubling of last year's allocation for the promotion of the rational use of drugs to 45 million yen; Pharma Japan says this is largely due to the wider availability of model hospital in-house drug information systems, whose numbers have now risen to six. Other allocations in the PAB's budget include:

- 3.13 billion yen for the support of R&D and the stable supply of pharmaceuticals - the same amount as last year;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight